Naloxone Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Naloxone Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Naloxone is an opioid antagonist used to counter the effects of opioid overdose, such as morphine and heroine. Naloxone is indicated for use in opioid overdose to counteract life-threatening depression of the central nervous system and respiratory system, allowing an overdose victim to breathe normally. Naloxone is non-scheduled prescription medication, which in most cases, is administrated by emergency response personnel or minimally trained personnel, and is thus ideal for treating overdose in people who are prescribed opioid pain medication. Naloxone can be administrated through parenteral route, by injecting in the muscle or vein.
Market Dynamics
Increasing launches and approval of new naloxone products in the market is expected to drive the global naloxone market growth over the forecast period. In October, 2016 Health Canada approved Narcan Nasal Spray 4 mg for non-prescription, community use in Canada
Rising prevalence of opioid overdose in key regions such as North America, and Europe is expected to drive demand for naloxone products and drive the naloxone market growth in the near future. For instance, according to the data published by European Monitoring Center for Drugs and Drug Addiction (EMCDDA), in 2016, around 150,943 high-risk opioid users were reported in Germany and around 330,445 were reported in the U.K.
Furthermore, initiatives by various government and private organizations to increase access of naloxone product among the population is also expected to drive market growth. For instance, in 2015, Kaleo, Inc. partnered with the Clinton Foundation and provided bulk discounts on its EVZIO to various college universities and public safety organizations.
Key features of the study:

This report provides in-depth analysis of naloxone market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global naloxone market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the naloxone market

Detailed Segmentation:

Global Naloxone Market, By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

Global Naloxone Market, By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

Global Naloxone Market, By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

Global Naloxone Market, By Geography:

North America

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

U.S.
Canada

Europe

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

GCC
Israel
Rest of Middle East

Africa

By Strength:

0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

By Drug Type:

Intranasal
Intramuscular/Subcutaneous
Intravenous

By Distribution Channel:

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Mylan N.V.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Novartis AG
Indivior Plc.
Adapt Pharma, Inc.
Amphastar Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Mundipharma International Limited
Kaleo, Inc.
Kern Pharma, S.L.

“*” marked represents similar segmentation in other categories in the respective section.